永泰生物-B(06978.HK)公佈年度業績 研發開支大增349.6% 多個在研產品已完成藥效學研究
格隆匯3月25日丨永泰生物-B(06978.HK)發佈公吿，截至2020年12月31日止年度，公司其他收入增加約107.9%至約人民幣600萬元。研發開支由截至2019年12月31日止年度約人民幣6200萬元增加約349.6%至2.79億元。
研發開支大幅增加主要是由於向研發員工提供購股權的影響、研發員工人數增加及增加對EAL臨牀試驗及其他研發管線產品的投資所致。
公司目前有多個TCR-T細胞在研產品正進行臨牀前研究，針對的靶抗原包括NY-ESO-1等睾丸癌抗原或胎盤癌抗原，以及EBV及HPV等病毒來源的抗原。公司計劃繼續投資於CAR-T及TCR-T細胞產品管線。具體而言，公司的NY-ESO-1TCR-T、CAR-T–19-DNR及aT19在研產品已完成藥效學研究，目標為於2021年底前進入臨牀試驗階段。
公司位於北京的研發及生產中心總面積約13,640平方米，當中包括質量檢驗大樓及潔淨實驗室，能夠支撐在研細胞免疫治療產品的臨牀前及臨牀研發，以及在研產品獲批上市後早期生產需求，而所有該等設施均已取得北京市藥檢所發出的潔淨廠房（區）檢驗報吿書。公司位於北京的國盛實驗室每年可處理約40,000份樣本，滿足產品管線兩至三年的臨牀試驗需求，以及EAL商業化的前期生產需求。此外，公司亦於大韓民國建立了一個研究中心，重點開發與公司業務相關的新技術。
公司表示，公司是一家開放性、前瞻性的免疫細胞技術產品研發公司。在內生增長的基礎上，公司擬擴大戰略合作及發掘併購機遇，以快速擴大覆蓋實體瘤及非實體瘤的產品管線。公司還將不斷地尋求新的潛在的細胞免疫治療產品，擴大戰略合作，通過選擇專業前景明確的產品，選擇性進行併購，進一步擴大公司的產品管線。公司計劃進一步增加投資，擴大參與進行中的EAL II期臨牀試驗的地區，以加快臨牀試驗入組及獲得所需數據的速度，同時提前進行未來的商業化佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
